A federal jury in Delaware said on Thursday that biotech company Amgen owes competitor Regeneron more than $406 million for ...

Tezepelumab demonstrated rapid and sustained clinical improvements in nasal polyp burden and symptom control, with effects ...

Shares of Bio-Techne Corp. slipped 7.27% to $47.86 Wednesday, on what proved to be an all-around mixed trading session for ...

Revisions to classification criteria ‘will ensure homogeneous trial populations’ with data-driven scoring, a standardized MRI ...

Carrie Fogliani is the president of GeneralCounselWest, PC, with 22 years of legal experience in healthcare law.

In the long-running feud between Regeneron and Amgen around the companies’ competing PCSK9 cholesterol meds, Regeneron has ...

Regeneron Pharmaceuticals won $406.8 million in damages for a lawsuit claiming Amgen violated antitrust and tort laws. A jury in a Delaware court found that Amgen violated certain laws, and gave ...

Shares of Amgen (AMGN) have been trending lower with the Health Care sector. But the sell off may soon come to an end.

Shares of Cisco Cisco Systems Inc. and Amgen Amgen Inc. have contributed to the blue-chip gauge's intraday rally, as the Dow Dow Jones Industrial Average was most recently trading 222 points (0.5%) ...

Regeneron's lead counsel was Jonathan D. Polkes of White & Case LLP.

U.S. lawmakers on Thursday asked Pfizer Inc for information on alleged comments by a former executive suggesting its research ...